Published in FEMS Microbiol Lett on December 08, 2014
Structure-based redesign of lysostaphin yields potent antistaphylococcal enzymes that evade immune cell surveillance. Mol Ther Methods Clin Dev (2015) 0.81
Discovery of novel S. aureus autolysins and molecular engineering to enhance bacteriolytic activity. Appl Microbiol Biotechnol (2015) 0.79
Genetically enhanced lysozyme evades a pathogen derived inhibitory protein. ACS Chem Biol (2015) 0.75
LytM Fusion with SH3b-Like Domain Expands Its Activity to Physiological Conditions. Microb Drug Resist (2016) 0.75
Peptidoglycan types of bacterial cell walls and their taxonomic implications. Bacteriol Rev (1972) 19.14
The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. Nat Protoc (2007) 9.92
The bacteria fight back. Science (2008) 5.76
LYSOSTAPHIN: ENZYMATIC MODE OF ACTION. Biochem Biophys Res Commun (1965) 4.94
Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev (2010) 4.76
An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus. Clin Infect Dis (2006) 2.98
Assessment of the Alamar Blue assay for cellular growth and viability in vitro. J Immunol Methods (1997) 2.78
The D-alanine residues of Staphylococcus aureus teichoic acids alter the susceptibility to vancomycin and the activity of autolytic enzymes. Antimicrob Agents Chemother (2000) 2.71
Dermcidin: a novel human antibiotic peptide secreted by sweat glands. Nat Immunol (2001) 2.29
Biofilm bacteria: formation and comparative susceptibility to antibiotics. Can J Vet Res (2002) 2.20
Interaction of cationic antimicrobial peptides with model membranes. J Biol Chem (2001) 2.16
The physiology of bacterial cell division. Ann N Y Acad Sci (2012) 1.97
Role of staphylococcal wall teichoic acid in targeting the major autolysin Atl. Mol Microbiol (2010) 1.82
Identification and molecular characterization of an N-acetylmuramyl-L-alanine amidase Sle1 involved in cell separation of Staphylococcus aureus. Mol Microbiol (2005) 1.72
Molecular cloning, sequencing, and expression of lytM, a unique autolytic gene of Staphylococcus aureus. J Bacteriol (1997) 1.70
Latent LytM at 1.3A resolution. J Mol Biol (2004) 1.64
Structure-activity analysis of buforin II, a histone H2A-derived antimicrobial peptide: the proline hinge is responsible for the cell-penetrating ability of buforin II. Proc Natl Acad Sci U S A (2000) 1.62
Studies on prolysostaphin processing and characterization of the lysostaphin immunity factor (Lif) of Staphylococcus simulans biovar staphylolyticus. Mol Microbiol (1997) 1.54
Crystal structures of active LytM. J Mol Biol (2005) 1.52
Lysins: the arrival of pathogen-directed anti-infectives. J Med Microbiol (2013) 1.43
Contribution of the Staphylococcus aureus Atl AM and GL murein hydrolase activities in cell division, autolysis, and biofilm formation. PLoS One (2012) 1.39
Microtiter susceptibility testing of microbes growing on peg lids: a miniaturized biofilm model for high-throughput screening. Nat Protoc (2010) 1.36
Molecular characterization of an atl null mutant of Staphylococcus aureus. Microbiol Immunol (2002) 1.35
Peptidoglycan hydrolase fusions maintain their parental specificities. Appl Environ Microbiol (2006) 1.35
Endolysins as antimicrobials. Adv Virus Res (2012) 1.33
LysK CHAP endopeptidase domain is required for lysis of live staphylococcal cells. FEMS Microbiol Lett (2008) 1.30
Staphylococcus aureus persisters tolerant to bactericidal antibiotics. J Mol Microbiol Biotechnol (2012) 1.25
Diverse antimicrobial killing by Enterococcus faecium E 50-52 bacteriocin. J Agric Food Chem (2008) 1.24
Chimeric phage lysins act synergistically with lysostaphin to kill mastitis-causing Staphylococcus aureus in murine mammary glands. Appl Environ Microbiol (2012) 1.15
Isolation and purification of enterocin E-760 with broad antimicrobial activity against gram-positive and gram-negative bacteria. Antimicrob Agents Chemother (2007) 1.14
Antibacterial activities of bacteriocins: application in foods and pharmaceuticals. Front Microbiol (2014) 1.12
Combination therapy with lysin CF-301 and antibiotic is superior to antibiotic alone for treating methicillin-resistant Staphylococcus aureus-induced murine bacteremia. J Infect Dis (2013) 1.09
Nutrient-dependent structural changes in S. aureus peptidoglycan revealed by solid-state NMR spectroscopy. Biochemistry (2012) 1.08
Determinants of murein hydrolase targeting to cross-wall of Staphylococcus aureus peptidoglycan. J Biol Chem (2012) 1.06
LytN, a murein hydrolase in the cross-wall compartment of Staphylococcus aureus, is involved in proper bacterial growth and envelope assembly. J Biol Chem (2011) 1.03
Bacteriophage virion-associated peptidoglycan hydrolases: potential new enzybiotics. Crit Rev Microbiol (2012) 1.02
Systematic peptide engineering and structural characterization to search for the shortest antimicrobial peptide analogue of gaegurin 5. J Biol Chem (2004) 1.01
Chimeric Ply187 endolysin kills Staphylococcus aureus more effectively than the parental enzyme. FEMS Microbiol Lett (2013) 0.98
Determination of lysozyme activities in a microplate format. Anal Biochem (2002) 0.97
Peptidoglycan hydrolases-potential weapons against Staphylococcus aureus. Appl Microbiol Biotechnol (2012) 0.96
In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone. J Antimicrob Chemother (2002) 0.96
Design and analysis of immune-evading enzymes for ADEPT therapy. Protein Eng Des Sel (2012) 0.95
Enhanced antimicrobial activity of engineered human lysozyme. ACS Chem Biol (2010) 0.93
Application of a high throughput Alamar blue biofilm susceptibility assay to Staphylococcus aureus biofilms. Ann Clin Microbiol Antimicrob (2009) 0.90
Aerosolized recombinant human lysozyme enhances the bactericidal effect of tobramycin in a hamster model of Pseudomonas aeruginosa-induced pneumonia. Exp Lung Res (2011) 0.87
DBAASP: database of antimicrobial activity and structure of peptides. FEMS Microbiol Lett (2014) 0.86
Novel chimerical endolysins with broad antimicrobial activity against methicillin-resistant Staphylococcus aureus. Microb Drug Resist (2012) 0.86
Design of a polypeptide FRET substrate that facilitates study of the antimicrobial protease lysostaphin. Biochem J (2009) 0.86
Gene and protein sequence optimization for high-level production of fully active and aglycosylated lysostaphin in Pichia pastoris. Appl Environ Microbiol (2014) 0.85
Anti-staphylococcal activities of lysostaphin and LytM catalytic domain. BMC Microbiol (2012) 0.85
Two novel antimicrobial peptides from centipede venoms. Toxicon (2009) 0.85
Physiological significance of the peptidoglycan hydrolase, LytM, in Staphylococcus aureus. FEMS Microbiol Lett (2010) 0.85
Aerosolized recombinant human lysozyme ameliorates Pseudomonas aeruginosa-induced pneumonia in hamsters. Exp Lung Res (2010) 0.85
Individual substitution analogs of Mel(12-26), melittin's C-terminal 15-residue peptide: their antimicrobial and hemolytic actions. FEBS Lett (2003) 0.85
Bioengineered lysozyme reduces bacterial burden and inflammation in a murine model of mucoid Pseudomonas aeruginosa lung infection. Antimicrob Agents Chemother (2013) 0.84
Staphylococcal phage 2638A endolysin is lytic for Staphylococcus aureus and harbors an inter-lytic-domain secondary translational start site. Appl Microbiol Biotechnol (2012) 0.82
Inhibition of the activity of both domains of lysostaphin through peptidoglycan modification by the lysostaphin immunity protein. Appl Environ Microbiol (2010) 0.81
Bioengineered lysozyme in combination therapies for Pseudomonas aeruginosa lung infections. Bioengineered (2014) 0.78